Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)

All study activities were consistent with the EU Directive 2001/20/EC section for non-interventional studies (i.e. observational studies). Medicinal products are prescribed in the usual manner in accordance with the terms of the marketing authorization. The assignment of the participant to a particular therapeutic strategy is not decided in advance by the trial protocol but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study.

Inclusion criteria

• Willingness to participate
• 18 years or older, either gender, any race
• Participant has relapsed at the end of the Part 1 follow-up phase (defined as having a positive virology result at 24 weeks of follow-up post treatment after a negative result at the Week 24 end-of-treatment time point)
• Participant considered suitable for treatment per local label
• Investigator considers suitable and participant consents to be treated

Exclusion criteria

• Pregnant women or those who plan to become pregnant or sexual partners of women who plan to become pregnant
• Participant does not qualify based on contra-indication, special warning, special population, and/or pregnancy & lactation section of the SmPC